Literature DB >> 1310770

Folding and processing of the capsid protein precursor P1 is kinetically retarded in neutralization site 3B mutants of poliovirus.

C Reynolds1, D Birnby, M Chow.   

Abstract

Poliovirus mutants in neutralizing antigenic site 3B were constructed by replacing the glutamic acid residue at amino acid 74 of capsid protein VP2 (VP2074E), using site-specific mutagenesis methods. All viable mutants display small-plaque phenotypes. Characterization of these mutants indicates that capsid assembly is perturbed. Although the defect in capsid assembly reduces the yield of mutant virus particles per cell, the resultant assembled particle is wild-type-like in structure and infectivity. Analyses of capsid assembly intermediates show a transient accumulation of the unprocessed capsid protein precursor, P1, indicating that cleavage of the mutant P1 by the 3CD protease is retarded. The mutant VP0-VP3-VP1 complex generated upon P1 cleavage appears assembly competent, forming pentamer and empty capsid assembly intermediates and infectious virion particles. Although the structure of the infectious mutant virus is virtually identical with that of the wild-type virus, the thermal stability of the mutant virus is dramatically increased over that of the wild-type virus. Thus, mutations at this residue are pleiotropic, altering the kinetics of capsid assembly and generating a virus that is more thermostable and more resistant to neutralization by the site 3B monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310770      PMCID: PMC240901     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Identification of residues in VP2 that contribute to poliovirus neutralization antigenic site 3B.

Authors:  C Reynolds; G Page; H Zhou; M Chow
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

2.  Myristoylation is important at multiple stages in poliovirus assembly.

Authors:  N Moscufo; J Simons; M Chow
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA.

Authors:  K Kirkegaard
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

4.  A mutant poliovirus containing a novel proteolytic cleavage site in VP3 is altered in viral maturation.

Authors:  W S Blair; S S Hwang; M F Ypma-Wong; B L Semler
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

5.  Stabilization of poliovirus against heat inactivation.

Authors:  B L Dorval; M Chow; A M Klibanov
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

6.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

7.  Genetic complementation among poliovirus mutants derived from an infectious cDNA clone.

Authors:  H D Bernstein; P Sarnow; D Baltimore
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

8.  Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats.

Authors:  M Chow; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus.

Authors:  D J Filman; R Syed; M Chow; A J Macadam; P D Minor; J M Hogle
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

View more
  7 in total

1.  RNA binding properties of poliovirus subviral particles.

Authors:  C I Nugent; K Kirkegaard
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

2.  Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties.

Authors:  Maria L Yakovenko; Elena A Cherkasova; Gennady V Rezapkin; Olga E Ivanova; Alexander P Ivanov; Tatyana P Eremeeva; Olga Y Baykova; Konstantin M Chumakov; Vadim I Agol
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Efficient analysis of nonviable poliovirus capsid mutants.

Authors:  J Simons; A Rogove; N Moscufo; C Reynolds; M Chow
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

4.  Is the 135S poliovirus particle an intermediate during cell entry?

Authors:  Y Huang; J M Hogle; M Chow
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Poliovirus mutants at histidine 195 of VP2 do not cleave VP0 into VP2 and VP4.

Authors:  M Hindiyeh; Q H Li; R Basavappa; J M Hogle; M Chow
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

6.  Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation.

Authors:  D C Ansardi; C D Morrow
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Cholesterol removal by methyl-beta-cyclodextrin inhibits poliovirus entry.

Authors:  Pranav Danthi; Marie Chow
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.